3-Benzoylamino-N-methyl-pyrrolidin | 13220-16-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Benzoylamino-N-methyl-pyrrolidin
• 英文别名: N-(1-methyl-pyrrolidin-3-yl)-benzamide；N-(1-methylpyrrolidin-3-yl)benzamide
• CAS: 13220-16-1
• 化学式: C₁₂H₁₆N₂O
• 分子量: 204.272
• InChiKey: FPKJRKVKFLQZRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] RORγ MODULATORS<br/>[FR] MODULATEURS DE ROR&Ggr;
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015035278A1

  公开（公告）日：2015-03-12

  Described are RORγ modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其药学上可接受的盐，其中所有取代基在此处定义。该发明包括公式I化合物的立体异构体形式，包括立体异构纯、立体混合和消旋形式，以及其互变异构体。还提供了包含相同化合物的药物组合物。这些化合物和组合物在调节细胞中的RORγ活性的方法以及治疗患有疾病或紊乱的受试者的方法中是有用的，其中受试者在调节RORγ活性方面会从中获益，例如自身免疫和/或炎症性疾病。
• [EN] PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF<br/>[FR] PYRROLO [2, 3-B] PYRIDINES OU PYRROLO [2, 3-B] PYRAZINES COMME INHIBITEUR DE HPK1 ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2019238067A1

  公开（公告）日：2019-12-19

  Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

  本文披露了一种公式（AIII）或（III）的化合物，或其立体异构体，或其药用可接受的盐，以及包含该化合物的药物组合物。还披露了一种利用本文披露的化合物治疗HPK1相关疾病或疾病的方法。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20120028920A1

  公开（公告）日：2012-02-02

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Otsuka Pharmaceutical Co., Limited

  公开号：EP2287161A1

  公开（公告）日：2011-02-23

  A heterocyclic compound or a salt thereof represented by the formula (I): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R1 represents a heteromonocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，由式（I）代表： 其中 R2 代表氢原子或低级烷基；A 代表低级亚烷基或低级亚烯基；R1 代表杂环基团。本发明的化合物对包括中枢神经系统疾病在内的精神疾病具有治疗范围广、无副作用、安全性高等特点。
• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10172845B2

  公开（公告）日：2019-01-08

  Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供的是式 I 的化合物： 或其药学上可接受的盐或溶液，其中 A、B、X1、X2、X3、X4、环 D、E、Ra、Rb、n 和 m 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可用 RET 激酶抑制剂治疗的疾病，包括 RET 相关疾病和失调。